NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free ARDX Stock Alerts $7.30 -0.11 (-1.48%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.25▼$7.5950-Day Range$7.30▼$9.7452-Week Range$3.16▼$10.13Volume6.72 million shsAverage Volume6.32 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$12.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ardelyx alerts: Email Address Ardelyx MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside69.3% Upside$12.36 Price TargetShort InterestBearish15.60% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.31Based on 8 Articles This WeekInsider TradingSelling Shares$1.34 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.38 out of 5 starsMedical Sector141st out of 938 stocksPharmaceutical Preparations Industry55th out of 423 stocks 4.6 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.36, Ardelyx has a forecasted upside of 69.3% from its current price of $7.30.Amount of Analyst CoverageArdelyx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.60% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Ardelyx has recently increased by 8.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 1.8 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ardelyx this week, compared to 4 articles on an average week.Search InterestOnly 36 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat FollowsOnly 30 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -9% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,343,678.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.44) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -24.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -24.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Ardelyx Stock (NASDAQ:ARDX)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesMarch 23, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Insider Sells $664,780.00 in StockMarch 28, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 25, 2024 | globenewswire.comArdelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and StrategyMarch 24, 2024 | americanbankingnews.comElizabeth A. Grammer Sells 86,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockMarch 21, 2024 | finance.yahoo.comInstitutional investors may overlook Ardelyx, Inc.'s (NASDAQ:ARDX) recent US$195m market cap drop as long-term gains remain positiveMarch 20, 2024 | ca.finance.yahoo.comARDX Apr 2024 7.500 putMarch 20, 2024 | ca.finance.yahoo.comARDX Apr 2024 10.000 callMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 19, 2024 | money.usnews.comArdelyx IncMarch 19, 2024 | americanbankingnews.comShort Interest in Ardelyx, Inc. (NASDAQ:ARDX) Expands By 11.8%March 16, 2024 | nasdaq.comGuru Fundamental Report for ARDXMarch 16, 2024 | investorplace.comThe Clock is Ticking: 3 Stocks Set to Explode in the Next QuarterMarch 16, 2024 | ca.finance.yahoo.comARDX Mar 2024 11.000 callMarch 16, 2024 | ca.finance.yahoo.comARDX Mar 2024 8.000 putMarch 16, 2024 | ca.finance.yahoo.comARDX Mar 2024 8.000 callMarch 15, 2024 | finance.yahoo.comARDX Mar 2024 8.500 callMarch 15, 2024 | finance.yahoo.comARDX Mar 2024 10.000 putMarch 13, 2024 | seekingalpha.comArdelyx Shrugs Off 'Mixed' Q4 EarningsMarch 12, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMarch 6, 2024 | finance.yahoo.comARDX Mar 2024 12.000 callMarch 6, 2024 | msn.comArdelyx spikes as kidney patient bill advances in CongressMarch 2, 2024 | finance.yahoo.comARDX Mar 2024 7.500 putMarch 2, 2024 | finance.yahoo.comARDX Mar 2024 7.500 callFebruary 28, 2024 | investorplace.comThe Millionaire's Watchlist: 3 Stocks Set for a Meteoric RiseFebruary 27, 2024 | globenewswire.comArdelyx to Participate at the Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsSee More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/29/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees267Year Founded2007Price Target and Rating Average Stock Price Target$12.36 High Stock Price Target$15.00 Low Stock Price Target$8.50 Potential Upside/Downside+69.3%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-53.08% Pretax Margin-52.65% Return on Equity-43.57% Return on Assets-26.03% Debt Debt-to-Equity Ratio0.30 Current Ratio4.88 Quick Ratio4.64 Sales & Book Value Annual Sales$124.46 million Price / Sales13.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book10.14Miscellaneous Outstanding Shares232,690,000Free Float219,888,000Market Cap$1.70 billion OptionableOptionable Beta0.88 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 59)President, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 60)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 52)MBA, Chief Financial & Operations Officer and Treasurer Comp: $623.7kMr. Robert FelschSenior VP of Finance & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 60)Chief Legal & Administrative Officer and Secretary Comp: $623.7kMs. Caitlin LowieVice President of Corporate Communications & Investor RelationsMs. Charon Spencer Sr.Chief Human Resources OfficerMr. David P. Rosenbaum (Age 63)Chief Development Officer Comp: $645.4kMr. Robert C. Blanks (Age 64)Chief Regulatory Affairs & Quality Assurance Officer Comp: $590.8kMore ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNGeronNASDAQ:GERNAmneal PharmaceuticalsNASDAQ:AMRXSchrödingerNASDAQ:SDGRAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsElizabeth A GrammerSold 86,000 sharesTotal: $664,780.00 ($7.73/share)Vanguard Group Inc.Bought 1,460,246 shares on 3/11/2024Ownership: 5.598%Wellington Management Group LLPBought 106,931 shares on 3/5/2024Ownership: 0.046%American International Group Inc.Bought 8,298 shares on 2/28/2024Ownership: 0.049%David P RosenbaumSold 5,183 sharesTotal: $47,683.60 ($9.20/share)View All Insider TransactionsView All Institutional Transactions ARDX Stock Analysis - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price target for 2024? 7 analysts have issued 1-year price objectives for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's stock price to reach $12.36 in the next year. This suggests a possible upside of 69.3% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2024? Ardelyx's stock was trading at $6.20 at the start of the year. Since then, ARDX stock has increased by 17.7% and is now trading at $7.30. View the best growth stocks for 2024 here. Are investors shorting Ardelyx? Ardelyx saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 36,310,000 shares, an increase of 8.0% from the February 29th total of 33,610,000 shares. Based on an average trading volume of 6,230,000 shares, the short-interest ratio is presently 5.8 days. View Ardelyx's Short Interest. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) announced its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. The biopharmaceutical company had revenue of $34.36 million for the quarter, compared to analyst estimates of $34.26 million. Ardelyx had a negative trailing twelve-month return on equity of 43.57% and a negative net margin of 53.08%. The business's revenue was down 22.2% compared to the same quarter last year. During the same period last year, the firm posted $0.06 EPS. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). Who are Ardelyx's major shareholders? Ardelyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.61%), Vanguard Group Inc. (5.60%), Eventide Asset Management LLC (2.93%), Rubric Capital Management LP (1.73%), Price T Rowe Associates Inc. MD (1.00%) and Price T Rowe Associates Inc. MD (1.00%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARDX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.